A global biopharmaceutical company partnered with ZS to identify the most promising tumor types for its novel antibody-drug conjugate. With limited internal data and a tight two-month deadline, the company needed a fast, reliable way to evaluate 60 tumor segments across 16 types.
ZS leveraged Intelligencia AI’s Portfolio Optimizer to streamline the process. Traditionally requiring four to six months, the analysis was completed in just over two. Intelligencia AI’s curated clinical and biological data enabled ZS to assess each segment’s commercial and clinical viability rapidly, narrowing the list to 10 high-potential targets.
The collaboration empowered confident investment decisions through:
- Granular tumor segmentation and competitive landscape analysis
- AI-driven probability of success assessments
- Rapid extraction of key metrics, such as phase 3 trial activity and modality approvals
ZS’s data-driven approach helped the client prepare for critical leadership discussions and allocate resources more strategically in oncology development.
Want to dive deeper into how AI transformed this decision-making process? Read the full case study on Intelligencia AI’s website.
Add insights to your inbox
We’ll send you content you’ll want to read – and put to use.
